Pharmaceutical company ChiRoClin said the U.S. Food and Drug Administration (FDA) has approved labeling updates for its ChiRhoStim agent.
ChiRhoStim (human secretin for injection), an orphan drug designed to aid in the diagnosis of pancreatic cancer and pancreatic exocrine dysfunction, is used with imaging modalities such as CT, endoscopic ultrasound, and MR cholangiopancreatography. The changes include elimination of the need to inject a test dose of ChiRhoStim and removal of the contraindication section in the package insert, both of which may shorten procedure time, according to the vendor.
The FDA has also approved ChiRhoStim for a five-year shelf life, ChiRoClin said.
